eravacycline   Click here for help

GtoPdb Ligand ID: 10805

Synonyms: compound 17j [PMID: 2148514] | TP-434 | TP434 | Xerava®
Approved drug PDB Ligand
eravacycline is an approved drug (EMA & FDA (2018))
Compound class: Synthetic organic
Comment: Eravacycline is a parenteral tetracycline antibacterial.
2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/). All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 11
Hydrogen bond donors 6
Rotatable bonds 6
Topological polar surface area 193.73
Molecular weight 558.21
XLogP 0.79
No. Lipinski's rules broken 2

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

✖
Canonical SMILES O=C(Nc1cc(F)c2c(c1O)C(=C1[C@@H](C2)C[C@@H]2[C@@](C1=O)(O)C(=C(C(=O)[C@H]2N(C)C)C(=O)N)O)O)CN1CCCC1
Isomeric SMILES O=C(Nc1cc(F)c2c(c1O)C(=C1[C@@H](C2)C[C@@H]2[C@@](C1=O)(O)C(=C(C(=O)[C@H]2N(C)C)C(=O)N)O)O)CN1CCCC1
InChI InChI=1S/C27H31FN4O8/c1-31(2)20-13-8-11-7-12-14(28)9-15(30-16(33)10-32-5-3-4-6-32)21(34)18(12)22(35)17(11)24(37)27(13,40)25(38)19(23(20)36)26(29)39/h9,11,13,20,34-35,38,40H,3-8,10H2,1-2H3,(H2,29,39)(H,30,33)/t11-,13-,20-,27-/m0/s1
InChI Key AKLMFDDQCHURPW-ISIOAQNYSA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)
No information available.
Summary of Clinical Use Click here for help
Eravacycline received EMA and FDA approval in 2018 as a treatment for complicated intra-abdominal infections (cIAIs).
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT01978938 Efficacy and Safety Study of Eravacycline Compared With Levofloxacin in Complicated Urinary Tract Infections Phase 3 Interventional Tetraphase Pharmaceuticals, Inc.
NCT03032510 Efficacy and Safety Study of Eravacycline Compared With Ertapenem in Participants With Complicated Urinary Tract Infections Phase 3 Interventional La Jolla Pharmaceutical Company
NCT01844856 Efficacy and Safety Study of Eravacycline Compared With Ertapenem in Complicated Intra-abdominal Infections Phase 3 Interventional Tetraphase Pharmaceuticals, Inc. Eravacycline demonstrated noninferiority to ertapenem as a treatment for cIAIs in this study. 1,3
NCT02784704 Efficacy and Safety Study of Eravacycline Compared With Meropenem in Complicated Intra-abdominal Infections Phase 3 Interventional La Jolla Pharmaceutical Company Eravacycline demonstrated noninferiority to meropenem as a treatment for cIAIs (including infections caused by resistant pathogens) in this study. 2-3
External links Click here for help
For extended ADME data see the following:

Drugs.com